keyword
MENU ▼
Read by QxMD icon Read
search

Infliximab therapeutic drug monitoring

keyword
https://www.readbyqxmd.com/read/28175214/p584-a-role-for-therapeutic-drug-monitoring-during-infliximab-induction-treatment-in-inflammatory-bowel-disease
#1
M Rasmussen, J Brynskov, M A Ainsworth, S Buhl, K Bendtzen, C Steenholdt
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28175187/p586-a-novel-approach-to-the-implementation-of-biosimilar-infliximab-ct-p13-for-the-treatment-of-ibd-utilising-therapeutic-drug-monitoring-the-edinburgh-experience
#2
N Plevris, A Deekae, G R Jones, T A Manship, C L Noble, J Satsangi, A G Shand, I D Arnott, C W Lees
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28175156/p645-the-introduction-of-infliximab-therapeutic-drug-level-monitoring-for-is-associated-with-cost-savings-in-a-cohort-of-patients-in-a-large-district-general-hospital
#3
S Whiteoak, H Johnson, C Hovell, S Weaver, S McLaughlin
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28175101/p440-therapeutic-drug-monitoring-of-infliximab-for-the-management-of-loss-of-response-in-inflammatory-bowel-disease-an-observational-multicenter-study
#4
D Pugliese, A Armuzzi, T Panici Tonucci, B Tolusso, C Felice, A Papa, L Cantoro, P Balestrieri, F Civitelli, L Bertani, A Kohn, M Cicala, F Viola, F Costa, G L Rapaccini, L Guidi
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28175050/p280-therapeutic-drug-monitoring-of-infliximab-and-adalimumab-for-detection-of-patients-at-risk-of-loss-of-response-in-inflammatory-bowel-disease
#5
J Gonzalez-Lopez, J M Giráldez-Montero, R Ferreiro, A Lorenzo, M J Lamas, J E Dominguez-Munoz, M Barreiro-de Acosta
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28175042/p248-the-new-infliximab-point-of-care-quantitative-test-can-equally-be-used-for-therapeutic-drug-monitoring-of-biosimilars-of-infliximab
#6
J Afonso, H T Sousa, I Rosa, J Carvalho, C C Dias, F Magro
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28173072/p648-the-impact-of-infliximab-therapeutic-drug-monitoring-on-decisions-made-in-a-virtual-biologics-clinic-for-ibd
#7
C Selinger, M Lenti, T Clark, H Rafferty, A O'Connor, T Ahmad, J Hamlin
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172976/p591-therapeutic-drug-monitoring-in-paediatric-inflammatory-bowel-disease-on-maintenance-infliximab-and-adalimumab-treatment-improves-clinical-remission-with-a-proactive-approach
#8
S Chadokufa, S Sider, B Huggett, T Sawney, N Shah, M Baycheva, A Zambrano Perez, N Acton, F Kiparissi
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172910/p460-early-use-of-therapeutic-drug-monitoring-to-individualize-infliximab-therapy-in-paediatric-ibd-a%C3%A2-multicentre-prospective-cohort-study
#9
E Crowley, N Carman, V Arpino, K Frost, A Ricciuto, M Sherlock, J Critch, D Mack, E Benchimol, K Jacobson, S Lawrence, J deBruyn, W El-Matary, A Otley, H Huynh, P Church, T Walters, A Griffiths
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28147368/combining-therapeutic-drug-monitoring-with-biosimilars-a-strategy-to-improve-the-efficacy-of-biologicals-for-treating-inflammatory-bowel-diseases-at-an-affordable-cost
#10
REVIEW
Ann Gils
BACKGROUND: Biologicals provide a tight disease control but not all patients respond favourably to treatment. Some patients do not respond at all (primary non-responders), while other patients respond initially but show loss of response over time (secondary non-responders). Drug concentrations in the serum of patients can be monitored and correlated with biological, clinical or endoscopic response. Therapeutic thresholds have been defined for infliximab and adalimumab. The European Medicines Agency has approved 3 biosimilars of infliximab and new biosimilars are waiting approval...
2017: Digestive Diseases
https://www.readbyqxmd.com/read/28079601/infliximab-optimization-based-on-therapeutic-drug-monitoring-in-pediatric-ibd
#11
Tatyana Hofmekler, Madeline Bertha, Courtney McCracken, Benadette Martineau, Elizabeth McKinnon, Bess T Schoen, Barbara O McElhanon, Gayathri Tenjarla, Subra Kugathasan, Cary Sauer
BACKGROUND: Infliximab (IFX) is an effective treatment for the management of moderate to severe inflammatory bowel disease (IBD). Low serum IFX levels are associated with the development of antibodies to IFX (ATI) which subsequently associated with clinical relapse and increased morbidity. The purpose of this study is to examine the relationship between dose and interval to IFX level. Secondary goal is to evaluate the relationship between IFX level and ATI in a pediatric IBD population...
June 21, 2016: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/27957480/the-utility-of-infliximab-therapeutic-drug-monitoring-among-patients-with-inflammatory-bowel-disease-and-concerns-for-loss-of-response-a-retrospective-analysis-of-a-real-world-experience
#12
Robert A Mitchell, Constantin Shuster, Neal Shahidi, Cherry Galorport, Mari L DeMarco, Gregory Rosenfeld, Robert A Enns, Brian Bressler
Background. Infliximab (IFX) therapeutic drug monitoring (TDM) allows for objective decision making in patients with inflammatory bowel disease (IBD) and loss of response. Questions remain about whether IFX TDM improves outcomes. Methods. Patients with IBD who had IFX TDM due to concerns for loss of response were considered for inclusion. Serum IFX trough concentration and anti-drug antibody (ADA) concentrations were measured. Patients were grouped by TDM results: group 1, low IFX/high ADA; group 2, low IFX/low ADA; group 3, therapeutic IFX...
2016: Canadian Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/27929524/rapid-test-for-infliximab-drug-concentration-allows-immediate-dose-adaptation
#13
Thomas Van Stappen, Lize Bollen, Niels Vande Casteele, Konstantinos Papamichael, Gert Van Assche, Marc Ferrante, Séverine Vermeire, Ann Gils
OBJECTIVES: Therapeutic drug monitoring of infliximab improves treatment outcomes, but available assays to monitor infliximab lack speed to implement treatment algorithms immediately. Our aim is to validate a rapid, lateral flow-based assay (LFA) for quantitative determination of infliximab and to assess thresholds associated with mucosal healing in patients with ulcerative colitis. METHODS: Samples (n=190) from 29 anti-tumor necrosis factor naive patients with ulcerative colitis starting infliximab induction therapy between June 2010 and February 2012 were prospectively collected...
December 8, 2016: Clinical and Translational Gastroenterology
https://www.readbyqxmd.com/read/27873119/validation-of-a-drug-resistant-anti-adalimumab-antibody-assay-to-monitor-immunogenicity-in-the-presence-of-high-concentrations-of-adalimumab
#14
Sumin Bian, Marc Ferrante, Ann Gils
With respect to patient safety and long-term efficacy, immunogenicity of therapeutic antibodies remains an important issue. Pre-treatment of samples using either higher temperature or acidification in order to separate drug/anti-drug antibody complexes has been implemented in the traditional bridging assay and an in-house-developed affinity capture elution assay but only a limited drug tolerance was obtained. In this study, we aim to apply a drug-resistant anti-drug antibody assay to adalimumab through a combination of adalimumab/anti-adalimumab antibody complex precipitation and acid dissociation...
November 21, 2016: AAPS Journal
https://www.readbyqxmd.com/read/27845027/clinical-effectiveness-and-cost-effectiveness-of-use-of-therapeutic-monitoring-of-tumour-necrosis-factor-alpha-tnf-%C3%AE-inhibitors-lisa-tracker%C3%A2-enzyme-linked-immunosorbent-assay-elisa-kits-tnf-%C3%AE-blocker-elisa-kits-and-promonitor%C3%A2-elisa-kits-versus-standard-care
#15
Karoline Freeman, Martin Connock, Peter Auguste, Sian Taylor-Phillips, Hema Mistry, Deepson Shyangdan, Rachel Court, Ramesh Arasaradnam, Paul Sutcliffe, Aileen Clarke
BACKGROUND AND OBJECTIVES: Systematic reviews and economic modelling of clinical effectiveness and cost-effectiveness of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [using LISA-TRACKER(®) enzyme-linked immunosorbent assay (ELISA) kits (Theradiag, Marne La Vallee, France, or Alpha Laboratories, Heriot, UK), TNF-α-Blocker ELISA kits (Immundiagnostik AG, Bensheim, Germany) and Promonitor(®) ELISA kits (Proteomika, Progenika Biopharma, Bizkaia, Spain)] versus standard care for Crohn's disease (CD)...
November 2016: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/27808043/optimizing-biological-treatment-in-rheumatoid-arthritis-with-the-aid-of-therapeutic-drug-monitoring
#16
Grith Petersen Eng
The treatment of rheumatoid arthritis (RA) has greatly improved with the use of biological TNF inhibitors (TNFi). These biopharmaceuticals target the inflammatory cytokine TNF, and hereby decrease the autoimmune inflammation, which may otherwise lead to permanent joint damage in the afflicted patients. Although TNFi decrease clinical disease activity in the majority of the treated patients, they are not always effective. Some patients have a partial response, some lose their initial response to treatment, and others never experience effect at all...
November 2016: Danish Medical Journal
https://www.readbyqxmd.com/read/27800265/treatment-of-juvenile-idiopathic-arthritis-associated-uveitis
#17
REVIEW
Merih Oray, İlknur Tuğal-Tutkun
Pediatric uveitis may be a serious health problem because of the lifetime burden of vision loss due to severe complications if the problem is not adequately treated. Juvenile idiopathic arthritis (JIA)-associated uveitis is characterized by insidious onset and potentially blinding chronic anterior uveitis. Periodic ophthalmologic screening is of utmost importance for early diagnosis of uveitis. Early diagnosis and proper immunomodulatory treatment are essential for good visual prognosis. The goal of treatment is to achieve enduring drug-free remission...
April 2016: Turkish Journal of Ophthalmology
https://www.readbyqxmd.com/read/27762509/analytical-and-clinical-evaluation-of-an-immunoassay-for-estimating-immunogenicity-of-infliximab-and-etanercept-in-indian-population
#18
Canna Ghia, Shashank Akerkar, Shailaja Sabnis, Urk Rao, Gautam Rambhad
BACKGROUND / OBJECTIVES: Biologic anti-TNFs in India have improved the patient management. Significant proportions of patients lose response over time or do not respond. Possible explanations are suboptimal trough anti-TNFa concentrations or antibodies to anti-TNFs. The aim of this project was to set up and standardize an independent laboratory to test immunogenicity of anti-TNF biologics (infliximab and etanercept). METHODS: Three rheumatologists piloted this project approved by independent ethics committee and carried out in compliance with ICH/GCP guidelines...
September 2016: Journal of the Association of Physicians of India
https://www.readbyqxmd.com/read/27665099/cost-effectiveness-of-drug-monitoring-of-anti-tnf-therapy-in-inflammatory-bowel-disease-and-rheumatoid-arthritis-a-systematic-review
#19
REVIEW
Laura Martelli, Pablo Olivera, Xavier Roblin, Alain Attar, Laurent Peyrin-Biroulet
BACKGROUND: Therapeutic drug monitoring (TDM) of anti-TNF is increasingly used to manage inflammatory bowel diseases (IBD) and rheumatoid arthritis (RA). The cost-effectiveness of this strategy is debated. METHODS: All studies comparing the cost-effectiveness of a TDM-based strategy and an empirical dose management of anti-TNF in IBD or RA were screened. Studies were identified through the MEDLINE electronic database (up to July 2016), and annual international meeting abstracts were also manually reviewed...
January 2017: Journal of Gastroenterology
https://www.readbyqxmd.com/read/27664854/standardization-of-the-homogeneous-mobility-shift-assay-protocol-for-evaluation-of-anti-infliximab-antibodies-application-of-the-method-to-crohn-s-disease-patients-treated-with-infliximab
#20
B Hernández-Breijo, M Chaparro, D Cano-Martínez, I Guerra, M Iborra, J L Cabriada, L Bujanda, C Taxonera, V García-Sánchez, I Marín-Jiménez, M Barreiro-de Acosta, I Vera, M D Martín-Arranz, F Mesonero, L Sempere, F Gomollón, J Hinojosa, J P Gisbert, L G Guijarro
BACKGROUND: The availability of a quantitative method to measure anti-infliximab (IFX) antibodies (ATI) would facilitate the implementation of therapeutic drug monitoring in clinical decision-making. Our aim was to standardize the homogeneous mobility shift assay (HMSA) used in the measure of ATI levels. METHODS: In this prospective longitudinal multicenter study, 50 IFX-treated Crohn's disease (CD) patients were followed up for 54weeks. During this period 360 human serum samples were analysed...
December 15, 2016: Biochemical Pharmacology
keyword
keyword
83590
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"